Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

Mark A. Socinski, MD
Published: Tuesday, Apr 25, 2017



Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

One of the ways immunotherapy can be improved is by the selection of the patients, explains Socinski. There is evidence that demonstrates that patients who strongly stain for PD-L1 have better outcomes.

There is also some encouraging data from the KEYNOTE-021 trial for combining immunotherapy with chemotherapy. Combining immunotherapy agents could have potential but it creates the risk for higher toxicities, states Socinski.
 


Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

One of the ways immunotherapy can be improved is by the selection of the patients, explains Socinski. There is evidence that demonstrates that patients who strongly stain for PD-L1 have better outcomes.

There is also some encouraging data from the KEYNOTE-021 trial for combining immunotherapy with chemotherapy. Combining immunotherapy agents could have potential but it creates the risk for higher toxicities, states Socinski.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x